Lintuzumab: Difference between revisions

{{Short description|Chemical compound}}

| verifiedrevid =

<!--Monoclonal antibody data-->

<!--Clinical data-->

<!--Pharmacokinetic data-->

<!--Identifiers-->

| ChemSpiderID =

| CAS_number_Ref = {{cascite||??}}

| CAS_number = 166089-32-3

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = V00Y10W60W

<!--Chemical data-->

'''Lintuzumab''' (SGN-33) is a [[ monoclonal antibody]] used in the treatment of [[cancer]]. The drug had been developed by [[Seattle Genetics]] as a treatment for [[acute myeloid leukemia]] (AML), a condition which results in the deaths of 9,000 people a year in the United States. Lintuzumab targets the [[CD33]] protein, which is expressed in AML and other [[myeloproliferative disease]]s, but does not appear in abundance on normal cells.

Lintuzumab had been in mid-stage clinical trial when pulled the drug in September 2010 after evidence showed that it did not lead to higher survival rates.<ref name=NYT>Pollack Andrew http://prescriptions.blogs.nytimes.com/2010/09/13/leukemia-drug-trial-fails Leukemia Drug Trial Fails [[The New York Times]] September 13, 2010</ref> The U.S. [[Food and Drug Administration]] and the [[European Medicines Agency]] had granted lintuzumab [[orphan drug]] status for treatment of AML and myelodysplastic .<ref name=SG>[http://www.seagen.com/product_pipeline_lintuzumab.shtml Lintuzumab (SGN-33)], Seattle Genetics. Accessed September 13, 2010.</ref>

The Phase IIb randomized, double-blind [[clinical trial]] studied 211 individuals ages 60 and over who had been enrolled by February 2009 and who were poor candidates for high-dose chemotherapy or had made the choice to reject the traditional chemotherapy treatment.<ref>Staff http://www.genengnews.com/gen-news-highlights/disappointing-phase-ii-data-leads-seattle-to-ditch-aml-candidate/81243912/ Disappointing Phase II Data Leads Seattle to Ditch AML Candidate [[Genetic Engineering & Biotechnology News]] September 13, 2010</ref> The study participants typically had a projected four to five months to live, with half treated with lintuzumab and a low dose of the agent [[cytarabine]], while the other half were given cytarabine in combination with a [[placebo]]. No patients were harmed in the trial and patients in both groups lived longer than expected, with those being given lintuzumab having a lower death rate. However, the study found that there was no benefit to patients on a statistical basis, and that it did not reduce the risk of infection or the need for [[blood transfusion]]s.<ref name=NYT/>

[[Gemtuzumab ozogamicin]] (marketed as Mylotarg), a similar drug from [[Pfizer]] that also targets the CD33 protein on leukemic cells, was withdrawn from the market in June 2010 after trials showed little benefit to patients.

==References==

*{{|=Feldman, Brandwein J Stone R Kalaycio M Moore J O'Connor J Wedel N Roboz, Miller C Chopra R Jurcic, Brown R Ehmann Schulman P Frankel, De Angelo D Scheinberg D|title=Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia |volume=23|issue=18|pages=4110–6 | = }}